Emea and the new pharmaceutical procedures for Europe D. B. JefferysK. H. Jones Special Article Pages: 471 - 476
Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension J. -M. DetryP. BlockThe Belgian Collaborative Study Group Pharmacoepidemiology and Prescription Pages: 477 - 481
Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency R. W. van OldenJ. J. M. van MeyelP. G. G. Gerlag Pharmacodynamics Pages: 483 - 488
Effects of somatostatin and loxiglumide on gallbladder motility R. J. LieverseM. C. W. JebbinkL. C. Rovati Pharmacodynamics Pages: 489 - 492
Efficacy and safety of the 200–300 mg sustained release formulation of diltiazem administered once daily in patients with stable angina B. TrimarcoD. RadzikJ. Ponsonnaille Pharmacodynamics Pages: 493 - 496
Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers J. P. De La CruzP. J. GarcíaJ. M. Smith-Agreda Pharmacodynamics Pages: 497 - 502
Debrisoquine hydroxylation in a Polish population P. K. KunickiD. SitkiewiczM. Radziwoń-Zaleska Pharmacokinetics and Disposition Pages: 503 - 505
Methotrexate in juvenile rheumatoid arthritis F. AlbertioniO. BeckP. Seideman Pharmacokinetics and Disposition Pages: 507 - 511
Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril J. M. T. van GriensvenR. C. SchoemakerH. -J. Röthig Pharmacokinetics and Disposition Pages: 513 - 518
Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal R. K. VerbeeckJ. I. MacdonaldR. J. Herman Pharmacokinetics and Disposition Pages: 519 - 523
Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism Y. CaracoE. Zylber-KatzE. M. Berry Pharmacokinetics and Disposition Pages: 525 - 530
Oral bioavailability of CHF1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy subjects under single dose and steady-state conditions X. DeroubaixA. StockisP. Ventura Pharmacokinetics and Disposition Pages: 531 - 536
Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese K. -M. ChuS. -M. ShiehO. Y. -P. Hu Pharmacokinetics and Disposition Pages: 537 - 542
Single dose pharmacokinetics of sumatriptan in healthy volunteers L. F. LaceyE. K. HusseyP. A. Fowler Pharmacokinetics and Disposition Pages: 543 - 548